SCHEMBL10077702

SCHEMBL10077702

COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(CO)c2)ccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 5/20 1.00
NFKB1 P19838 3/20 1.00
MMP2 P08253 2/20 1.00
MMP8 P22894 2/20 1.00
APP P05067 10/20 0.82
MAPT P10636 9/20 0.82
BACE1 P56817 5/20 0.82
CYP2D6 P10635 2/20 0.82
CYP2C9 P11712 2/20 0.82
TSHR P16473 2/20 0.82
HSD17B10 Q99714 2/20 0.82
ABCB1 P08183 2/20 0.82
AKR1B1 P15121 2/20 0.82
MAOA P21397 2/20 0.82
MAOB P27338 2/20 0.82
MMP13 P45452 2/20 0.82
HDAC3 O15379 2/20 0.82
HDAC1 Q13547 2/20 0.82
HDAC2 Q92769 2/20 0.82
HDAC6 Q9UBN7 2/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12565705 1.00 MMP9 (1.00) MMP9NFKB1MMP2MMP8APP
SCHEMBL13125782 1.00 MMP9 (1.00) MMP9NFKB1MMP2MMP8APP
SCHEMBL16203057 1.00 MMP9 (1.00) MMP9NFKB1MMP2MMP8APP
SCHEMBL6847537 0.91 MMP9 (0.84) MMP9NFKB1MMP2MMP8APP
SCHEMBL13453148 0.91 MMP9 (0.84) MMP9NFKB1MMP2MMP8APP
SCHEMBL26397843 0.91 MMP9 (0.84) MMP9NFKB1MMP2MMP8APP
SCHEMBL13324431 0.91 NFKB1 (0.83) MMP9NFKB1MMP2MMP8APP
Curcumin SCHEMBL8336603 0.90 APP (1.00) MMP9NFKB1MMP2MMP8APP
Curcumin SCHEMBL8440 0.90 APP (1.00) MMP9NFKB1MMP2MMP8APP
Curcumin SCHEMBL250984 0.90 APP (1.00) MMP9NFKB1MMP2MMP8APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12029706-B2 Methods for treating mucopolysaccharidosis UNIVERSITY OF MIAMI (US) 2024-07-09 US disclosed
US-11872236-B2 Pharmacological agents for treating ocular diseases CALASIA PHARMACEUTICALS, INC. (US) 2024-01-16 US disclosed
US-20230400771-A1 ON-PRESS DEVELOPMENT TYPE LITHOGRAPHIC PRINTING PLATE PRECURSOR, METHOD OF PREPARING LITHOGRAPHIC PRINTING PLATE, AND LITHOGRAPHIC PRINTING METHOD FUJIFILM CORPORATION (JP) 2023-12-14 US disclosed
US-11839637-B2 Neuron activator KINJIRUSHI CO., LTD. (JP) 2023-12-12 US disclosed
US-20230285573-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2023-09-14 US disclosed
US-11744840-B2 N-palmitoyl-D-glucosamine in a micronized form INNOVET ITALIA S.R.L. (IT) 2023-09-05 US disclosed
US-20230226814-A1 ON-PRESS DEVELOPMENT TYPE LITHOGRAPHIC PRINTING PLATE PRECURSOR, METHOD OF PREPARING LITHOGRAPHIC PRINTING PLATE, AND LITHOGRAPHIC PRINTING METHOD FUJIFILM CORPORATION (JP) 2023-07-20 US disclosed
US-20230190839-A1 COMPOSITIONS AND COMBINATIONS FOR SUBJECTS SUFFERING FROM ENDOMETRIOSIS GYNOV (FR) 2023-06-22 US disclosed
US-20230161247-A1 ON-PRESS DEVELOPMENT TYPE LITHOGRAPHIC PRINTING PLATE PRECURSOR, METHOD OF PREPARING LITHOGRAPHIC PRINTING PLATE, AND LITHOGRAPHIC PRINTING METHOD FUJIFILM CORPORATION (JP) 2023-05-25 US disclosed
US-20180078535-A1 THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF IONS PHARMACEUTICAL S.À R.L. (LU) 2018-03-22 US disclosed
US-20100260671-A1 COMPOUNDS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AMYLOID ASSOCIATED DISEASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-10-14 US disclosed
US-20100216859-A1 CURCUMIN ANALOG COMPOSITIONS AND RELATED METHODS CHARLESSON, LLC 2010-08-26 US disclosed
US-20100190978-A1 METHYLENE BLUE - CURCUMIN ANALOG FOR THE TREATMENT OF ALZHEIMER'S DISEASE CODMAN & SHURTLEFF, INC. 2010-07-29 US disclosed
US-7745670-B2 Curcumin-Resveratrol hybrid molecule CODMAN & SHURTLEFF, INC. (US) 2010-06-29 US disclosed
US-7723515-B1 Methylene blue—curcumin analog for the treatment of alzheimer's disease CODMAN & SHURTLEFF, INC. (US) 2010-05-25 US disclosed
US-20090326275-A1 USE OF NITROGEN-CONTAINING CURCUMIN ANALOGS FOR THE TREATMENT OF ALZHEIMERS DISEASE DEPUY SPINE, LLC 2009-12-31 US disclosed
US-20090325963-A1 Iontophoretic Delivery of Curcumin and Curcumin Analogs for the Treatment of Alzheimer's Disease CODMAN & SHURTLEFF, INC. 2009-12-31 US disclosed
US-20090087385-A1 Intranasally administering curcumin in a bolus of helium gas to treat alzheimers disease CODMAN & SHURTLEFF, INC. 2009-04-02 US disclosed
US-20070204412-A1 Curcumin and its derivatives for use as silicone colorants GELEST, INC. (US) 2007-09-06 US disclosed
US-20070204412-A1 Curcumin and its derivatives for use as silicone colorants GELEST, INC. (US) 2007-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216859-A1 CURCUMIN ANALOG COMPOSITIONS AND RELATED METHODS PTGIS, HMOX1, PTGS1 MMP9 63/4885NFKB1 42/4885MMP2 150/4885
US-20100190978-A1 METHYLENE BLUE - CURCUMIN ANALOG FOR THE TREATMENT OF ALZHEIMER'S DISEASE APP, PSEN2, MAPT MMP9 602/4885NFKB1 667/4885MMP2 862/4885
US-20090326275-A1 USE OF NITROGEN-CONTAINING CURCUMIN ANALOGS FOR THE TREATMENT OF ALZHEIMERS DISEASE SLC1A3, SLC1A1, SLC1A2 MMP9 2581/4885NFKB1 495/4885MMP2 3006/4885
US-11744840-B2 N-palmitoyl-D-glucosamine in a micronized form NAPEPLD, FABP2, FSCN1 MMP9 462/4885NFKB1 343/4885MMP2 619/4885
US-20230285573-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE NEDD4, CBL, UBQLN2 MMP9 4666/4885NFKB1 619/4885MMP2 3970/4885
US-20180078535-A1 THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF INMT, HNMT, COMT MMP9 2837/4885NFKB1 1602/4885MMP2 1432/4885
US-20230190839-A1 COMPOSITIONS AND COMBINATIONS FOR SUBJECTS SUFFERING FROM ENDOMETRIOSIS SQSTM1, TSG101, SUCNR1 MMP9 867/4885NFKB1 340/4885MMP2 1383/4885
US-11872236-B2 Pharmacological agents for treating ocular diseases CRYAA, CRYAB, TTR MMP9 3961/4885NFKB1 1082/4885MMP2 1302/4885
US-12029706-B2 Methods for treating mucopolysaccharidosis GAA, MAN2B1, IDUA MMP9 345/4885NFKB1 4698/4885MMP2 170/4885
US-20100260671-A1 COMPOUNDS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AMYLOID ASSOCIATED DISEASES APP, HTT, SCN3A MMP9 3034/4885NFKB1 1948/4885MMP2 2728/4885
US-11839637-B2 Neuron activator BDNF, DBH, CHAT MMP9 2867/4885NFKB1 688/4885MMP2 2522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.